MRI helps doctors select best treatment for early breast cancers

October 17, 2005

Breast magnetic resonance imaging enhances patient selection for accelerated, partial breast irradiation by detecting previously unsuspected, microscopic lesions within the breast, according to a study presented October 17, 2005, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver. The study shows that almost 10 percent of patients who had a breast MRI before completing breast conservation treatment had additional disease that was previously not seen on the patient's mammogram (breast X-ray).

For patients with early stage breast cancer, the current standard treatment involves surgery to remove the tumor (lumpectomy) followed by a course of external beam radiation to the entire breast over a six to seven week period to kill any remaining cancer cells. Alternatively, radiation oncologists are studying accelerated partial breast irradiation, which reduces the radiation course to just one to five days for a select group of women with early-stage breast cancer.

In this study, doctors performed not only standard mammography, but also breast MRI in order to determine as accurately as possible the extent of the patient's tumor, as well as the presence of any unsuspected disease elsewhere in the breast. Of the 51 patients reported, almost 10 percent had additional cancer identified on the MRI that was not appreciated on the mammogram. This additional disease meant the patients were perhaps more safely treated with wider removal of breast tissue followed by whole breast radiation therapy, or mastectomy (surgical removal of the breast) in cases of biopsy-proven multicentric disease.

"At this point, we feel that partial breast irradiation is best reserved for women with unifocal carcinoma, excised with tumor-free margins, without evidence of multifocal or multicentric disease. Breast MRI may help radiation oncologists identify the most suitable candidates for this accelerated treatment to minimize the chance that a woman's cancer will return near the original tumor or elsewhere in the breast," said Kathleen Horst, M.D., lead author of the study and a radiation oncologist at the Stanford Cancer Center in Stanford, California.

For more information on radiation therapy for breast cancer, please visit www.rtanswers.org.

Dr. Horst will be presenting her study at 10:15 a.m. on October 17 in Room 205 of the Colorado Convention Center. If you would like a copy of the abstract, "Breast Magnetic Resonance Imaging Alters Patient Selection for Accelerated, Partial Breast Irradiation" or would like to speak to the lead author of the study, Kathleen Horst, M.D., please call Beth Bukata or Nick Lashinsky October 16-20 in the ASTRO Press Room at the Colorado Convention Center at 303-288-8454 or 303-228-8455. You may also e-mail them at bethb@astro.org or nickl@astro.org.
-end-
ASTRO is the largest radiation oncology society in the world, with more than 8,000 members who specialize in treating patients with radiation therapies. As a leading organization in radiation oncology, biology and physics, the Society is dedicated to the advancement of the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.

American Society for Radiation Oncology

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.